Skip to main content
Clinical Trials/NCT06371352
NCT06371352
Recruiting
Not Applicable

Effect of Intermittent and Continuous Theta Burst Stimulation on Sleep Quality, Sleep Propensity, Daytime Sleepiness, and Fatigue in Depression

Jakub Antczak1 site in 1 country90 target enrollmentMay 15, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Unipolar Depression
Sponsor
Jakub Antczak
Enrollment
90
Locations
1
Primary Endpoint
Pittsburgh Sleep Quality Index
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

Intermittent and continuous theta-burst stimulation (iTBS and cTBS respectively) are the newer modalities of transcranial magnetic stimulation with documented efficacy in treatment of depressed mood but with conflicting results regarding their efficacy in treatment of other symptoms of depression such as insomnia, daytime sleepiness and fatigue. This study will investigate the efficacy of iTBS over the left dorsolateral prefrontal cortex (DLPFC) and cTBS over the right DLPFC, compared to sham stimulation, in treatment of insomnia, daytime sleepiness and fatigue in depression.

Detailed Description

Intermittent and continuous theta-burst stimulation (iTBS and cTBS respectively) are the newer modalities of conventional repetitive transcranial magnetic stimulation (rTMS) with documented noninferiority in improving mood in depressive disorders. The effect of both modalities on other significant depression symptoms has not been studied. In this feasibility study investigators aim primarily to assess the safety and therapeutic potential of iTBS over the left dorsolateral prefrontal cortex (lDLPFC) and cTBS over the right dorsolateral prefrontal cortex (rDLPFC) on sleep quality, sleep propensity, fatigue, and daytime sleepiness in patients with major and bipolar depression.

Registry
clinicaltrials.gov
Start Date
May 15, 2024
End Date
May 2027
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor Investigator
Principal Investigator

Jakub Antczak

Clinical Professor

Jagiellonian University

Eligibility Criteria

Inclusion Criteria

  • severe or moderate depressive episode (according to international classification of diseases (ICD)-10) without psychotic symptoms at the time of inclusion
  • Diagnosis of major depression (F33.1 or F33.2) or bipolar disorder (F31.3 or F31.4).
  • The score of the Athens Insomnia Scale five or more
  • Unchanged antidepressive pharmacotherapy at least one month prior to inclusion

Exclusion Criteria

  • Contraindications to transcranial magnetic stimulation, including ferromagnetic elements in head, pregnancy and epilepsy
  • Psychotic symptoms at the time of inclusion
  • Suicidal ideations and/or attempts within three months prior to inclusion

Outcomes

Primary Outcomes

Pittsburgh Sleep Quality Index

Time Frame: Before intervention - four weeks after finishing intervention.

Pittsburgh Sleep Quality Index is a questionnaire to identify sleep disturbances. It consists of a combination of Likert-type and open-ended questions, which are later converted to scaled scores. Scores for each question range from 0 to 3, with higher scores indicating greater sleep disturbances. The minimum value of the total score is 0 and the maximum is 21 with higher scores meaning worse outcome. Change from the baseline to the measurement done after finishing intervention, to the measurement done two weeks after finishing intervention to the measurement done four weeks after finishing intervention.

Beck Depression Inventory 2

Time Frame: Before intervention - four weeks after finishing intervention.

Inventory consisting of 21 items measuring cognitive, affective, somatic, and vegetative symptoms of depression. Each item is scored from 0 to 3, with a higher score denoting more severe depression. Items are related to the criteria from the Diagnostic and Statistical Manual of Mental Disorders-IV. The minimum value of the total score is 0 and the maximum is 63 with higher scores meaning worse outcome. Change from the baseline to the measurement done after finishing intervention, to the measurement done two weeks after finishing intervention to the measurement done four weeks after finishing intervention.

Secondary Outcomes

  • Sleep propensity non-rapid eye movement 2 sleep stage(Through study completion, an average of 1 year)
  • Brief Psychiatric Rating Scale(Before intervention - four weeks after finishing intervention.)
  • Epworth Sleepiness Scale(Before intervention - four weeks after finishing intervention.)
  • Sleep propensity non-rapid eye movement 1 sleep stage(Through study completion, an average of 1 year)
  • Quality of Life in Depression Scale(Before intervention - four weeks after finishing intervention.)
  • Fatigue Assessment Scale(Before intervention - four weeks after finishing intervention.)

Study Sites (1)

Loading locations...

Similar Trials